This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiang, Z. Q.
Right arrow Articles by Ertl, H. C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiang, Z. Q.
Right arrow Articles by Ertl, H. C. J.

 Previous Article  |  Next Article 

Journal of Virology, October 2003, p. 10780-10789, Vol. 77, No. 20
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.20.10780-10789.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

Z. Q. Xiang,1 G. P. Gao,2 A. Reyes-Sandoval,1 Y. Li,1 J. M. Wilson,2 and H. C. J. Ertl1*

The Wistar Institute,1 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania2

Received 7 May 2003/ Accepted 14 July 2003

E1 deletion adenoviral vectors of the human serotype 5 (AdHu5) and the chimpanzee serotype 68 (AdC68) expressing the rabies virus glycoprotein (rab.gp) were tested for induction of transgene product-specific antibodies upon intranasal or oral immunization of newborn mice. Both vectors induced antibodies to rabies virus that could be detected in serum and mucosal secretions. Serum rabies virus-neutralizing antibody titers sufficed to protect neonatally vaccinated mice against a subsequent challenge with rabies virus. The efficacy of the AdHu5rab.gp vector given orally to newborn mice born to AdHu5-immune dams was not impaired by maternally transferred antibodies to the vaccine carrier.


* Corresponding author. Mailing address: The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104. Phone: (215) 898-3863. Fax: (215) 898-3953. E-mail: ertl{at}wistar.upenn.edu.


Journal of Virology, October 2003, p. 10780-10789, Vol. 77, No. 20
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.20.10780-10789.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Kohlmann, R., Schwannecke, S., Tippler, B., Ternette, N., Temchura, V. V., Tenbusch, M., Uberla, K., Grunwald, T. (2009). Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus. J. Virol. 83: 12601-12610 [Abstract] [Full Text]  
  • Holman, D. H., Penn-Nicholson, A., Wang, D., Woraratanadharm, J., Harr, M.-K., Luo, M., Maher, E. M., Holbrook, M. R., Dong, J. Y. (2009). A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity. CVI 16: 1624-1632 [Abstract] [Full Text]  
  • Wang, L., Cheng, C., Ko, S.-Y., Kong, W.-P., Kanekiyo, M., Einfeld, D., Schwartz, R. M., King, C. R., Gall, J. G. D., Nabel, G. J. (2009). Delivery of Human Immunodeficiency Virus Vaccine Vectors to the Intestine Induces Enhanced Mucosal Cellular Immunity. J. Virol. 83: 7166-7175 [Abstract] [Full Text]  
  • Swenson, D. L., Wang, D., Luo, M., Warfield, K. L., Woraratanadharm, J., Holman, D. H., Dong, J. Y., Pratt, W. D. (2008). Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections. CVI 15: 460-467 [Abstract] [Full Text]  
  • Baez-Astua, A., Herraez-Hernandez, E., Garbi, N., Pasolli, H. A., Juarez, V., zur Hausen, H., Cid-Arregui, A. (2005). Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses. J. Virol. 79: 12807-12817 [Abstract] [Full Text]  
  • Hashimoto, M., Boyer, J. L., Hackett, N. R., Wilson, J. M., Crystal, R. G. (2005). Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity. Infect. Immun. 73: 6885-6891 [Abstract] [Full Text]  
  • Berg, M., DiFatta, J., Hoiczyk, E., Schlegel, R., Ketner, G. (2005). Viable adenovirus vaccine prototypes: High-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc. Natl. Acad. Sci. USA 102: 4590-4595 [Abstract] [Full Text]